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Abstract. – OBJECTIVE: Although many pre-
vious meta-analyses of epidemiological stud-
ies have demonstrated a relationship between 
body mass index (BMI) and mortality, inconsis-
tent findings among cardiovascular disease pa-
tients have been observed. Thus, we performed 
an umbrella review to understand the strength 
of evidence and validity of claimed associations 
between BMI and mortality in patients with car-
diovascular diseases. 
MATERIALS AND METHODS: We compre-
hensively re-analyzed the data of meta-analy-
ses of observational studies and randomized 
controlled trials on associations between BMI 
and mortality among patients with cardiovas-
cular diseases. We also assessed the strength 
of evidence of the re-analyzed outcomes, which 
were determined from the criteria including sta-
tistical significance of the p-value of random-ef-
fects, as well as fixed-effects meta-analyses, 
small-study effects, between-study heterogene-
ity, and a 95% prediction interval.
RESULTS: We ran comprehensive re-analysis 
of the data from the 21 selected studies, which 
contained a total of 108 meta-analyses; 23 were 
graded as convincing evidence and 12 were sug-
gestive, 42 were weak, and 23 were non-signif-
icant. 
CONCLUSIONS: Underweight increased mor-
tality in acute coronary syndrome (ACS), heart 
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failure, and after therapeutic intervention for 
patients with cardiovascular diseases. Over-
weight, on the other hand decreased mortality 
in patient’s ACS, atrial fibrillation, and heart fail-
ure with convincing evidence.
Key Words:
BMI, Cardiovascular disease, Meta-analysis, Mortal-
ity, Obesity, Umbrella review.
Introduction
Global prevalence of overweight and obesity 
in adults has risen by 27.5% between 1980 and 
20131. Body mass index (BMI) is widely used as 
a clinical tool to assess the grade of adiposity and 
can be easily calculated from the ratio of body 
weight in kilograms divided by height in meters 
squared (kg/m2)1. According to the definition of 
the National Institutes of Health (NIH) and World 
Health Organization (WHO), BMI can be cate-
gorized as follows: underweight (<18.5 kg/m2), 
normal (18.5-24.9 kg/m2), overweight (25-29.9 kg/
m2), and obesity (≥30 kg/m2)2,3. Obesity further 
can be classified into 3 classes of severity: class I 
obesity (30-34.9 kg/m2), class II obesity (35-39.9 
kg/m2) and class III obesity (≥40.0 kg/m2)2.
It is well recognized that obesity is associat-
ed with all-cause mortality [hazard ratio (HR) 
1.18, (95% confidence interval (CI), 1.12 to 1.25] 
in the general population4. Many epidemiological 
studies and their meta-analyses on the association 
between BMI and mortalities in patients with 
cardiovascular disease (CVD) were published re-
cently. However, the results have been inconsistent 
and “obesity paradox” related results are reported 
among meta-analyses5-7 and, therefore, the current 
evidence is insufficient and controversial to con-
fidently define the relationship between BMI and 
mortality in patients with various CVDs, including 
those with acute coronary syndromes (ACS), those 
with most ACS patients survive, or those with 
atrial fibrillation (AF). Additionally, we explored 
the same relationship following multiple CVD 
therapy modalities, such as coronary artery by-
pass graft surgery (CABG), and post percutaneous 
coronary interventions (PCI). Finally, we explored 
the correlation between BMI and mortality among 
patients with heart failure (HF).
Different types of biases in literature can con-
tribute to inconsistent associations between BMI 
and mortality among patients with CVDs in 
different studies. Therefore, it is necessary to 
estimate a more accurate association by integrat-
ing the various statistical parameters8,9. Recently, 
many researchers apply the umbrella review con-
cept10, which re-evaluates the results of previous-
ly published systematic reviews and meta-anal-
yses and determines the strength of evidence 
across multiple associations to help clinicians and 
patients make informed clinical decisions. The 
aim of this study was to provide an overview of 
the strength of evidence by assessing the extent 




We performed an umbrella review of me-
ta-analyses and systematic reviews on the asso-
ciations between BMI and mortality in patients 
with CVDs. This umbrella review and meta-anal-
ysis was conducted and reported according to the 
Preferred Reporting Items for Systematic Re-
views and Meta-Analyses (PRISMA) guideline11. 
The PRISMA checklist is shown in Supplemen-
tary Table I.
Literature Search Strategy 
The search was conducted by three authors 
(DDP, JIS, and RAG). We systematically searched 
PubMed from inception to June 1st, 2018 to identi-
fy meta analyses examining associations between 
BMI and mortality in patients with CVDs. The 
keywords used for the search were ‘(body mass 
index OR BMI) AND (mortality OR death) AND 
(meta OR meta-analysis) AND (cardiovascular 
diseases OR CVD)’. We screened articles by ti-
tles, abstracts, and full texts to identify eligible 
meta-analyses.
Eligibility and Inclusion/Exclusion Criteria 
Studies were included in our analysis if they 
(1) were systematic reviews of either prospective 
or retrospective observational study designs, (2) 
investigated the association between BMI and 
mortality in patients with CVDs (3) defined pa-
tients’ overweight, underweight, and obesity sta-
tus using BMI, (4) conducted meta-analysis, and 
(5) reported individual study estimates and their 
95% CIs. Studies were excluded if they (1) did not 
conduct meta-analysis, (2) were not about BMI 
and mortality in CVD patients, (3) analyzed mor-
tality in infants, general populations, or patients 
with cancers, and (4) did not included individual 
study data available for re-analysis. The detailed 
process of this screening is shown in Figure 1.
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Extraction of Data 
We extracted the following data from the ob-
tained eligible articles: the name of first author, 
published year, study design, BMI categories, 
type of patients, outcome measures, the number 
of deaths, the total number of population, type 
of metrics [HR, or odds ratio (OR) or risk ratio 
(RR)], the effect sizes and 95% CI of individ-
ual studies in each meta-analysis, and random 




We performed re-analysis of each meta-anal-
ysis using individual study estimates extract-
ed from each meta-analysis. We obtained the 
summary estimate of both random-effects and 
fixed-effects and obtained p-values12. Statistical 
significance was claimed at 0.05. Heterogeneity 
across the individual studies was assessed using 
a metric of inconsistency and the p-value of the 
-based Cochrane Q test.  values of<25%, 25%-
50%, 50-75% and>75% were judged to be low, 
moderate, large, and very large heterogeneity, 
respectively13. In addition, we assessed wheth-
er there existed small study effects by using 
the Egger’s test of asymmetry (one-tailed Egger 
p-value<0.05 indicates presence of small-study 
effect)14,15. We also estimated the 95% predic-
tion interval (PI). While random-effects sum-
mary estimate addresses the mean of the effects 
of the individual studies, the PI estimates the 
interval in which the true effect of a new future 
study will fall within, thereby further accounting 
for between-study heterogeneity16. All statistical 
analyses were performed using ‘Comprehensive 
meta-analysis version 3.3.070’ software (Borest-
ein, NH, USA).
Determining the Level of Evidence: 
Convincing, Suggestive, Weak, and 
Non-Significant 
We, then, graded the level of evidence of each 
result of the meta-analysis based on a scheme ap-
plied in previously published umbrella reviews8,9. 
The criteria were as follows:
Convincing evidence: (1) both fixed-effects 
and random-effects p-values <0.001, (2) low 
or moderate heterogeneity (I2 <50), (3) 95% PI 
excluding the null hypothesis, (4) no evidence 
of small-study effect and (5) random summa-
ry estimate and the effect of the largest study 
having concordance in terms of statistical 
significance. 
Suggestive evidence: (1) both fixed-effects 
and random-effects p-values <0.005, (2) low or 
moderate heterogeneity (I2 <50), (3) no evidence 
of small-study effect, (4) random summary esti-
mate and the effect of the largest study having 
concordance in terms of statistical significance, 
and does not meet criteria for convincing evi-
dence. 
Figure 1. Flow chart of literature 
search.
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Weak evidence: both fixed-effects and ran-
dom-effects p-values <0.05 and does not meet 
criteria for suggestive evidence. 
Non-significance: fixed-effects or random-ef-
fects p-value>0.05.
If a meta-analysis included only two individual 
studies, assessment of small-study effects and 
95% PIs was not possible. Therefore, it was at 
best graded as weak level of evidence.
Among the individual studies that were classi-
fied as having weak evidence due to high hetero-
geneity (I2>50%), we further evaluated whether 
such high heterogeneity was caused by the dif-
ferences in the direction of individual effects9. 
When the number of statistically significant in-
dividual studies was the same or greater than 
the number of individual studies which were not 
significant or statistically significant in the oppo-
site direction, we speculated that the high hetero-
geneity in this case was caused by the differences 
in the magnitude of the effects rather than the 
differences in the direction of individual effects. 
Therefore, in these cases, we upgraded the level 
of evidence to suggestive or convincing when the 
criteria other than heterogeneity were satisfied.
Results
Study Characteristics 
Using the pre-specified inclusion and exclusion 
criteria, 21 eligible articles corresponding to 108 
meta-analyses were finally included in our review 
(Figure 1)5,6,17-35. The 108 meta-analyses studied 
10 CVD sub-categories. We classified the me-
ta-analyses into eight cohorts according to CVDs 
classification as follows: (1) ACS/post myocardial 
infarction (MI)/after ACS; (2) Post-coronary an-
giography (CAG); (3) Post-PCI; (4) Chronic HF; 
(5) HF; (6) AF; (7) following left ventricular assist 
device (LVAD) implantation; (8) after cardiac sur-
gery; and (9) after transcatheter aortic valve im-
plantation (TAVI). All the comparisons are sum-
marized in Tables I-III. Twenty-three were graded 
as convincing evidence, while 12 were suggestive, 
42 were weak, and 23 were non-significant. The 
remaining levels of evidence could not be assessed 
and were referred to as not available (N/A).
Acute Coronary Syndrome (ACS)
Three articles studied the association between 
BMI and mortality in patients with ACS (Table 
Table I. Association between overweight and morality in cardiovascular diseases; acute coronary syndrome, post-CABG, and post PCI.
Continued
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I). These studies investigated the association be-
tween BMI and mortality in terms of all-cause 
mortality and in-patient mortality. In several 
studies, mortality was classified into short-term 
(<30 days) and long-term (1-2 years or >3 years) 
according to the duration of follow-up5,17,18. One 
study, which included 9 cohort studies, compared 
underweight and normal BMI patients, and the 
meta-analysis demonstrated positive associations 
for mortality regardless of the duration of fol-
low-up or type of mortality (Table I). The evi-
dence, however, was considered weak17. 
Three studies reported a total of 103 cohorts and 
36 observational studies for overweight patients and 
patients with severe obesity and mortality among 
patients with ACS, acute MI and those patients 
Table I (Continued). Association between overweight and morality in cardiovascular diseases; acute coronary syndrome, post-CABG, and post PCI.
Abbreviations: ACS, acute coronary syndrome; AMI, acute myocardial infarction; BMI, body mass index; C, cohort study; CABG, coronary artery bypass graft; 
Co, concordance; CV, cardiovascular; E,Egger p-value; HR, hazard ratio; L, large effect; M, mortality; N, no; No, number of study; N/A, not available; NL, normal; 
O, observational study; Ob, Obese; OR, odds ratio; OW, overweight; PCI, percutaneous coronary intervention; PI, prediction interval; RCT, randomized control 
trial; RR, relative risk; S, small-study effect; SOb, severe obese; T, type of study, TM, Type of metrics; TP, type of patients; UW, underweight; Y, yes. †Number of 
individual studies showing statistically significant decreased mortality for overweight (R) /not statistically significant (N) /statistically significant increased mortality 
(I) for overweight, compared to normal BMI. llong-term (1-5 years), s short term (<30 days), 5 > 5 years, 30 30 day mortality.
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following an acute MI. Protective associations were 
observed for both short-term (<30days) and long-
term (1-2 years or longer) follow-up related to all-
cause mortality and in-hospital mortality5,17,18. 
One analysis was classified as convincing evi-
dence. The analysis showed that in patients with 
ACS, obesity, compared to normal BMI had a 
protective effect with a reanalyzed RR of 0.6 
(0.51 to 0.69) (Table I)5. 
No protective associations for mortality were 
observed in obese patients compared to over-
weight patients in patients with acute MI (Table 
I). In patients following acute MI, obesity and 
overweight compared to normal BMI were both 
protective; however, the evidence was suggestive 
and weak, respectively17,18. 
Post-CABG
There were two studies regarding patients post 
CABG, including 38 cohort and 44 observational 
analysis19,20. The only two convincing evidences 
were on the protective effects of obesity and 
overweight protective effects, with OR of 0.62 
(0.55 to 0.7) and 0.7 (0.63 to 0.77) respectively 
compared to patients with normal weight. These 
effects were observed in short-term follow-up, 
less than 30 days19. The majority of evidence were 
either weak or showed no association of BMI and 
mortality in patients after CABG surgery. The 
evidence for the association between overweight 
and normal BMI patients on mortality was grad-
ed as weak evidence due to the large heterogene-
ity. However, no evidence for other results was 
Table II. Association between overweight and morality in HF.
Abbreviations: BMI, body mass index; C, cohort; Co, concordance; CHF, chronic heart failure CV, cardiovascular; E, Egger p-value; EF, ejection fraction; Hi vs Lo, 
Highest vs lowest category of post-HF diagnosis BMI ;HF, heart failure; HR, hazard ratio; I, increase; LBMI, low BMI (<20); MOb, Morbid obese;N, no; N/A, not 
available; O, Observational; OR, odds ratio; P, preserved; R&C, RCT/cohort; RCT, randomized control trial; RR, relative risk; S, small-study effect; Y, yes.†Number 
of individual studies showing statistically significant decreased mortality for overweight (R) /not statistically significant (N) /statistically significant increased 
mortality (I) for overweight, compared to normal BMI.
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suggestive because in those results, we had no 
similar or greater number of statistically signif-
icant individual studies compared to individual 
studies that were not significant19.
Post-PCI
Our search yielded the largest amount of evi-
dence for mortality among patients after PCI and 
its relationship to BMI. In total, we included five 
scientific papers that comprised 129 observation-
al studies, 91 cohorts and 58 observational/RCT 
studies6,19,20,22,23. Patients who underwent a PCI 
and were underweight demonstrated an increased 
risk of mortality in all of the studies. All mea-
sures of mortality, including short-term (30 days 
in-hospitals mortality), medium follow-up (1-2 
and 3 years) and long term follow-up (more than 
5 years) showed a higher risk of mortality among 
patient with low BMI or underweight. However, 
the only convincing evidence were for those with 
a mortality at 1-3 years and all-cause mortality in 
underweight patients with a RR of 2.33 (1.87 to 
2.91) and 2.52 (1.69 to 3.75) respectively6,23, and in 
patients with low BMI with a RR of 2.65 (2.19 to 
3.2) for all-cause mortality20.
Both overweight and obesity had an impressive 
number of convincing evidences, all convergent 
toward a protective effect against mortality in all 
follow up periods6,19-21,23. More specifically, obesi-
ty vs. normal BMI showed convincing evidence 
for patients who had in-hospital mortality, 1-year 
mortality, 30 days mortality and all-cause mortal-
ity. The strongest and most significant protective 
association was in those patients with obesity vs. 
normal weight at 1-year mortality [RR=0.5 (95% 
PI=0.43 to 0.59)]. These results were highly reli-
able as the criteria for the convincing evidence 
were all satisfied: statistically significant with a 
p-value of less than 0.01, no small-study effect 
and with a small heterogeneity and 95% PI ex-
cluding the null21. Severe obesity did not have 
a valid protective effect vis-à-vis mortality in 
patient following PCI. All of the studies showed 
either weak evidence or no association with a 
non-statistical significance (p-values greater than 
0.01) and 95% PI that includes the null hypothe-
sis.
Heart Failure (HF)
All results showed that regardless of the type 
of study design and the characteristics of the 
participating population, underweight was as-
sociated with an increase in mortality, while 
overweight was associated with a decrease in 
Table III. Association between overweight and morality in transcatheter aortic valve implantation, cardiac surgery, atrial fibrillation and left ventricular assist device.
Abbreviations: Afib, atrial fibrillation; ALVAD , after LVAD inplantation; BMI, body mass index; C, cohort; CS, cardiac surgery; CV, cardiovascular; HR, hazard 
ratio; LVAD, left ventricular assist device; LT, long term; M, mortality; N, number; No, number of studies; N/A, not available; NL, normal; Ob, obese; P, preserved; 
R&C, RCT & cohort study; RCT, randomized control trial; RR, relative risk, S, small number of studies; ST, short term; T, type of metrics; TAVI, trans-catheter aortic 
valve implantation, Y, yes. † Number of individual studies showing statistically significant decreased mortality for overweight (R) /not statistically significant (N) /
statistically significant increased mortality (I) for overweight, compared to normal BMI.
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all-cause and cardiovascular mortality in HF 
patients. Compared to normal BMI, underweight 
increased all-cause mortality with one study hav-
ing convincing evidence27. For patients who were 
underweight or with those BMI between 18.5 and 
23.9, we found multiple studies with convincing 
evidence that associated them with increase mor-
tality. In patients with chronic HF, both RCT/co-
hort and observational studies reported a RR for 
all-cause mortality of 1.25 (1.9 to 1.31) and 1.27 
(1.17 to 1.37) respectively24,25, with statistically 
significant p-value of less than 0.01, and 95% PI 
that does not include the null hypothesis. This 
relationship was also applicable to patients with 
HF. However, the evidence was weak for patients 
with East Asian HF26. 
In all studies among patients with chronic HF, 
the RR pointed towards a protective effect of 
obesity in term of all-cause and cardiovascular 
mortality24,25. However, none of the evidence was 
convincing. Moreover, one cohort study showed 
no association25. Only 3 RCT/cohort studies were 
analyzed with regard to patients with severe obe-
sity compared to those with non-elevated BMI, 
and found only suggestive evidence of protection 
against all-cause mortality in patients with chronic 
HF24. An increase in five units of BMI among HF 
patients was associated with decreased all-cause 
mortality, one study showed weak evidence (dis-
cordant direction)29 and the other others showed no 
association in the case of HF mortality30. Similarly, 
for HF with preserved ejection fraction (HFpEF), 
one observational cohort showed a weak protective 
association against all-cause mortality, while the 
other cohort study showed no association31. When 
HF and chronic HF taken together, there was no 
convincing level of evidence that overweight and 
obesity had lower all-cause and cardiovascular 
mortality compared to normal BMI, with three 
suggestive and 12 weak, and five with no asso-
ciation levels of evidences, respectively. Finally, 
for East Asian HF patients26, studies revealed 2 
suggestive level of evidence for patients with BMI 
more than 28 and those with BMI between 24 and 
27.9 compared to normal BMI. The only convinc-
ing protective evidence against all-cause mortality 
was in those with East Asian HF with a 5-unit 
increase in BMI26. 
Transcatheter Aortic Valve Implantation 
(TAVI)
One meta-analysis evaluated the association 
between BMI and mortality based on short term 
and long-term survival32. There were positive 
associations between underweight (BMI<20) and 
normal weight (BMI 20-24.9) in both short- and 
long-term mortalities. In contrast, obese patients 
(BMI>30) had negative associations in both 
short- and long-term mortalities compared with 
normal weight (BMI 20-24.9). Because all class-
es of obese (Class I~III) patients were grouped 
together as BMI>30, the association between the 
individual obesity class and mortality was uncer-
tain. The evidence for short-term mortality was 
non-significant for both underweight and obesity 
groups due to large random p-value. On the other 
hand, the evidence for the relationship between 
underweight and obese patients and long-term 
mortality were weak.
Cardiac Surgery
Re-analysis of the data from meta-analyses 
revealed that underweight was associated with 
increased 30-day mortality (RR =1.75, 1.34 to 
2.29) with weak evidence33. Overweight, obesity 
I, II, III groups all had lower incidences of death 
compared to normal BMI. The evidences for 
associations with mortality were suggestive in 
obesity II and obesity III whereas the evidence 
was weak for overweight and obesity I.
Atrial Fibrillation (AF)
There was one selected study regarding AF. 
One study showed that underweight patients had 
more than a doubled risk for all-cause and car-
diovascular mortality compared to the normal 
BMI group34. However, the risk of mortality 
decreased dramatically in overweight and obese 
patients. Because the study did not include se-
vere or morbid obese patients in the analysis, it 
was unclear whether such dramatic decrease in 
mortality would also be observed in these BMI 
groups. Through our study, it was found that the 
meta-analysis had either weak or non-significant 
evidence. Further studies are needed to improve 
the level of evidence.
Following LVAD Implantation
We reviewed one paper that included 31 ob-
servational studies exploring the relationship of 
mortality among patients post LVAD implanta-
tion in relation to their BMI35. All RR of the stud-
ies pointed towards protective effects of obesity 
vs. non-obesity regarding mortality. However, 
the only convincing evidence was the short-term 
all-cause mortality. The RR of these four obser-
vational studies was 0.79 (0.73 to 0.86), p-value 
of less than 0.01, and with no small-study effect. 
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Even though all other researches showed similar 
results, three of them showed no association and 
one had a weak evidence. Thus, overall, the ev-
idence points that obesity among patients after 
LVAD implantation might be associated with 
mortality, except for a potential benefit for short-
term over-all mortality. Since the patients in this 
study were not categorized into underweight, 
overweight and obese groups, the association 
between each group and mortality was not as-
sessable. Thus, further investigations are needed 
to provide more information.
Discussion
Our study demonstrates the associations be-
tween BMI and risk of various kinds of mortal-
ities such as all-cause mortality, cardiovascular 
mortality or others among patients with CVDs. 
We comprehensively re-analyzed the data of 19 
meta-analyses and found that a very large pro-
portion had weak or non-significant evidence. 
Only ten meta-analyses had convincing evidence 
and this corresponds to 52.6% of the total me-
ta-analyses. The positive association between 
underweight and mortality in HF, and patients 
after PCI, and the negative association between 
overweight and mortality in ACS, patients after 
PCI, CABG and LVAD insertion, and finally 
those with East Asian HF had convincing ev-
idences. Suggestive evidence was found in 10 
(9.4%) and weak evidence was observed in 37 
(35%) meta-analyses. 55 (51.8%) meta-analyses 
results were not statistically significant and 15 
(14.1%) could not be graded due to several rea-
sons such as (1) there was only one study result 
or (2) small-study effects could not be calculated 
due to small number of studies (<3 studies). The 
results of our study are in line with those of other 
umbrella reviews showing that there have been 
many claims of statistical significance for most 
of the studied associations, but only a minority 
of these associations have robust supporting ev-
idence without hints of bias36,37. Currently, it has 
been suggested that there is massive production 
of unnecessary, misleading, and conflicted sys-
tematic reviews and meta-analyses, because most 
topics have overlapping, redundant meta-analyses 
and some results are often produced either by in-
dustry employees or by authors with industry ties 
whose results aligned with sponsor interests38. 
We also found that there have been overlapping 
meta-analyses on the same topic in our umbrel-
la review and further strategies to improve the 
quality of meta-analyses may be important in the 
future39.
In addition, most of the current meta-analy-
ses mainly present their results with random- or 
fixed-effects size and 95% CI with p-value. Re-
cently, however, reporting of the level of evidence 
has gained more importance to increase the val-
ue of the publication and reduce misleading re-
sults10,40. To determine the noteworthiness of the 
results, further calculations, such as between-study 
heterogeneity, small-study effects, 95% PIs, the 
concordance between the results of meta-analyses 
and the largest study, have been suggested8,9,36,37. 
Therefore, convincing evidence can be obtained 
after meeting all of these more stringent statistical 
criteria to reduce the biases for the claimed associ-
ation. Through our umbrella review, we found that 
caution should be applied when interpreting the re-
sults of meta-analyses in addition to the statistical 
criteria for level of evidence.
Globally, the incidence of obesity is increas-
ing at an alarming rate leading consequently 
to a rising incidence of accompanying diseases 
such as CVDs41. To note, obesity by itself is an 
independent predictor for CVDs even if it is not 
associated with any risk factors42. Historically, 
and up until the writing of this report, clinicians, 
rightfully so, consider obesity as detrimental for 
both CVD primary and secondary preventions ef-
forts42. However, evidence has indicated that the 
co-existence of obesity in CVD patients might 
have potential protective effects. Our umbrella re-
view is exactly in concordance with this well-es-
tablished “obesity paradox”43-45. This paradox 
has been proven repeatedly in other conditions 
such as hypertension and patients with congenital 
heart diseases46. 
The landmark Framingham study and a large 
body of evidence have laid ground to linking 
obesity as a strong risk factor for HF47. The exact 
mechanism is still poorly understood; however, it 
is thought to be secondary to a shift in the body 
composition of fat and lean muscles leading to a 
state of low-grade systematic inflammation43,48. 
However, despite this gloomy association, scien-
tists have explored a potential paradoxical pro-
tective effect49 and growing body of research is 
showing survival benefits in obese patients with 
HF19,50,51. Even though the underlying physiolog-
ical process is far from being comprehended46. 
The increase in lean muscle might play a central 
role in the protective process by increasing car-
dio-respiratory fitness index52,53.
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These effects are reproducible in patients with 
coronary heart diseases. Obesity in its abso-
lute presence predisposes to a pro-inflammatory 
state and increases atherosclerotic plaques in the 
coronary and contributes to their instability54,55. 
However, comparable to those patients with HF, 
obesity was found to be paradoxically beneficial 
with more favorable prognosis56-58. The same shift 
in body composition is also thought to be at the 
roots of the described protective effects46. In ad-
dition to the benefits of increasing lean muscle 
mass, increase adiposity in obese patients have 
been proposed to provide protective properties59 
especially in those sub-set of patients with mini-
mal systemic inflammation60.
Overall, multiple hypotheses have attempted 
to explain the obesity paradox. As discussed 
previously, the change in body composition, with 
regards to fat composition and lean muscle pro-
portion. This hypothesis has been supported clin-
ically by the detrimental effects of cachexia, 
especially in patients with HF61. Although more 
research is needed, several observational study 
also showed correlation between low BMI and 
cardiovascular disease51,62. Sarcopenia (involun-
tary weight loss), cardiac cachexia, and increased 
catabolic status were possible mechanisms of 
poor prognosis in lower BMI patients63-65. Our 
study also showed six convincing evidence that 
low BMI (or underweight) increase mortality 
especially in post-PCI and HF patients. Addition-
ally, the observed lower mortality in patients with 
CVD may stem from normal physiologic hemo-
stasis. Molecules, such as NT-proBNP, which are 
lower in obese people, may play a protective role 
against mortality66,67. Finally, in obese patients, 
adipokines, such as adiponectin and leptin may 
play a key role in protection and better survival. 
Leptin may have been providing protection from 
mortality, especially in patients with HF. Its ef-
fects are thought to counteract the pro-inflamma-
tory cytokines TNF-alpha on the heart muscles 
leading to improved survivals68,69. Similarly, sup-
porting this hypothesis, low levels of leptin and 
adiponectin, such as cardiac cachexia, weight and 
adipose loss, have been associated with reduced 
survivals68,70-73. 
To note, BMI itself may not be an accurate 
measurement for adiposity or body composition 
since it also reflects lean body mass74. Lean body 
mass represents muscle mass and better fitness, 
which is considered as protective. Misclassifi-
cation as overweight or obese might be the case 
in some with large muscle mass and normal ad-
iposity who were misclassified as overweight or 
obese74. To resolve this potential BMI miss-inter-
pretation, a more precise parameter must be used 
to measure fat mass. One suggestion is the use of 
waist-to-hip or waist-to-thigh ratio as measures 
of adiposity. Another suggestion is the use of the 
InBody Test, which provides a comprehensive 
view of body composition75.
Even though our umbrella review is the first of 
its kind and provided results in accordance with 
existing literatures, there are some limitations 
due to the nature and abundance of the analyzed 
studies. First, we found that the vast majority of 
the selected studies used in the meta-analysis 
used retrospective cohorts, meaning each in-
dividual study is vulnerable to the biases such 
as small number of studies, restrictive area of 
studied region of this design. Second, the most 
commonly used outcome in the meta-analysis 
was all-cause mortality, and thus, there is the 
possibility that other patient characteristics, apart 
from BMI, could be associated with increased 
risk of mortality. For instance, cancers, bleeding, 
injuries, infections, and others are all possible 
causes of death that can contribute to all-cause 
mortality. Each patient has a different suscepti-
bility. Potential confounding factors should be 
adjusted for prior to the selection of participants 
for meta-analysis; however, we found that most 
meta-analyses did not adjust for these confound-
ing factors, which should further be considered in 
future meta-analyses.
Third, there were unclear mortality outcomes 
in some studies. Namely, there are different types 
of mortality outcomes reported among different 
studies, such as all-cause, cardiovascular, and 
in-hospital mortality. However, in some investi-
gations the mortality types were not mentioned 
clearly, and thus it was not possible to identify 
whether they refer to all-cause or other types of 
mortality. Moreover, mortality can be classified 
according to the duration of follow-up. Studies 
of ACS or MI reported mortality in terms of fol-
low-up duration. However, one study reporting 
mortality outcomes17 did not describe follow-up 
in detail and therefore, it requires caution when 
interpreting the results. 
Fourth, there were some meta-analyses, where 
patients were not classified into one clear BMI 
category. Instead multiple BMI categories were 
grouped together for analysis. In addition, the 
cut-off of high BMI differed among studies such 
that some meta-analyses classified obese patients 
into different classes according to severity of 
BMI and mortality in patients with cardiovascular disease
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obesity, whereas in other systemic reviews and 
meta-analysis, patients with BMI ≥30 were de-
fined as high BMI76. Thus, it is very important 
to classify each patient into the appropriate BMI 
category and clarify the type of morality outcome 
in meta-analysis studies to prevent misinterpre-
tation. 
Fifth, there were a fairly large proportion of 
meta-analyses where the strength of evidence 
was not available due to a small number of stud-
ies (n≤2). When the number of studies is small, 
statistical results such as Egger’s p-value and 
95% PI cannot be obtained. Therefore, we were 
not able to determine the strength of evidence in 
these studies. Finally, the criteria we used were 
not definitive for assessing the level of evidence. 
Despite the presence of limitations as stat-
ed above (mostly meta-analyses themselves), our 
study makes key contributions. First of all, to 
our best knowledge, this study is the first in 
determining the strength of evidences for the as-
sociation between BMI categories and mortality 
in patients with CVDs. Furthermore, the diseases 
investigated in this study are clinically important 
and the results of our study are meaningful when 
assessing the mortality outcomes in a real clinical 
setting.
Conclusions
Our study provides supplemental evidence 
supporting the “obesity paradox” effect that is 
widely accepted by now in the scientific and 
medical community. Although there is no con-
sensus regarding the optimal range of BMI for 
lowering mortality in the diseases investigated in 
this study, we believe that further vigorous me-
ta-analyses can continue to inform research and 
practice, and strengthen assessment, prognosis, 
and clinical decision-making and targeted phar-
macological therapies.
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